fintols

Bristol Myers Squibb vs Pfizer (BMY vs PFE)

Bristol Myers Squibb trades at 13.2x earnings vs 40.1x for Pfizer; Bristol Myers Squibb grows sales faster (+6.9% vs -0.4%). Debt and dividend, Nov 2026.

Quick answer

On today's data (November 19, 2026): Bristol Myers Squibb looks cheaper on P/E: 13.2x against 40.1x for Pfizer. Bristol Myers Squibb grows faster: sales +6.9% against -0.4% for Pfizer in the latest quarter. Bristol Myers Squibb has the better net margin: 18.5% against 6.3% for Pfizer.

This is a snapshot of the numbers, not a recommendation to buy or sell.

Analyze Bristol Myers Squibb freeAnalyze Pfizer free

Your first analysis is free with a free account, no card.

Short answer

On P/E as of November 19, 2026, Pfizer is the more expensive of the two: it trades at 40.1x its annual earnings against 13.2x for Bristol Myers Squibb. Bristol Myers Squibb sells prescription drugs in a single segment. Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. What helps read that gap: Pfizer sales -0.4% against +6.9% for Bristol Myers Squibb in the latest quarter; net margin 6.3% against 18.5%; net debt for Pfizer: 2.0x EBITDA against 1.8x EBITDA. A higher P/E is not by itself a buy or a sell signal: it is a snapshot of today.

Bristol Myers Squibb (BMY) and Pfizer (PFE) compete in healthcare and pharma. Here are Bristol Myers Squibb and Pfizer side by side with their real figures as of November 19, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Bristol Myers Squibb or Pfizer.

Bristol Myers Squibb vs Pfizer: the figures

FigureBristol Myers SquibbPfizer
Share price$59.56 (November 18, 2026)$28.06 (November 18, 2026)
Market cap$121.7 billion$159.9 billion
P/E (TTM)13.2x40.1x
Forward P/E8.9x9.5x
Revenue growth (quarter)+6.9%-0.4%
Net margin (TTM)18.5%6.3%
Net debt / EBITDA1.8x2.0x
Dividend yield4.23%6.13%
Beta0.190.30

Bristol Myers Squibb and Pfizer figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 19, 2026; N/A means that Bristol Myers Squibb or Pfizer figure is not available, and we never estimate it.

3 key differences between Bristol Myers Squibb and Pfizer

  1. Valuation: Pfizer trades at 40.1x its annual earnings and Bristol Myers Squibb at 13.2x; the market pays more for each dollar of Pfizer profit, usually because it expects more growth.
  2. Profitability: for every 100 of sales, Bristol Myers Squibb keeps 18.5 as net profit and Pfizer keeps 6.3.
  3. Dividend: Pfizer yields 6.13% at today's price and Bristol Myers Squibb yields 4.23%.

Bristol Myers Squibb or Pfizer: which fits your profile

Neither Bristol Myers Squibb nor Pfizer wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

Verdict: Bristol Myers Squibb or Pfizer?

Of the 6 comparable figures in the table, Bristol Myers Squibb stands out on 5 (sales growth, net margin, lower P/E, less debt over EBITDA and lower volatility (beta)) and Pfizer stands out on 1 (dividend yield). That does not name a winner between Bristol Myers Squibb and Pfizer: the table is a snapshot of today, not a forecast.

You are halfway through

Keep reading free.

Create your free account to continue reading “Bristol Myers Squibb vs Pfizer (BMY vs PFE)”.

No card required

That easy

Three steps. Zero spreadsheets.

  1. 1Search a companyBy the name you know it: Apple, Inditex, Santander… ETFs too.
  2. 2Fintols does the homeworkIt reads the official filings, runs the numbers and writes the analysis for you.
  3. 3You analyze and decideWith the five answers clear, you decide. And you save the analysis to review it when the price moves.
Analyze any stock free
Analyze BMY free